Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation (Narrative) (Details)

v2.4.0.8
Basis of Presentation (Narrative) (Details) (USD $)
3 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended 3 Months Ended 12 Months Ended 3 Months Ended
Mar. 31, 2014
segment
drug
Mar. 31, 2013
Dec. 31, 2013
Mar. 31, 2014
Equipment
Minimum
Mar. 31, 2014
Equipment
Maximum
Apr. 30, 2013
Royalty Stream and Milestone Payments Purchase Agreement with Selexis
program
Mar. 31, 2014
Cydex Pharmaceuticals, Inc
Mar. 31, 2013
Cydex Pharmaceuticals, Inc
Dec. 31, 2013
Cydex Pharmaceuticals, Inc
Jan. 31, 2011
Cydex Pharmaceuticals, Inc
Jan. 31, 2012
Cydex Pharmaceuticals, Inc
Guaranteed Payment
Mar. 31, 2014
Cydex Pharmaceuticals, Inc
Revenue Sharing
Mar. 31, 2013
Cydex Pharmaceuticals, Inc
Revenue Sharing
Jan. 31, 2010
Metabasis Therapeutics
right
Mar. 31, 2014
Metabasis Therapeutics
Mar. 31, 2013
Metabasis Therapeutics
Dec. 31, 2013
Metabasis Therapeutics
Mar. 31, 2014
Accounts Receivable
Customer Concentration Risk
customer
Dec. 31, 2013
Accounts Receivable
Customer Concentration Risk
customer
Mar. 31, 2014
Acquired In Process Research And Development
Mar. 31, 2013
Acquired In Process Research And Development
Property, Plant and Equipment [Line Items]                                          
Accumulated deficit $ 669,242,000   $ 671,339,000                                    
Working capital 12,400,000                                        
Period for which available resources are sufficient to satisfy company's anticipated operating and capital requirements 12 months                                        
Earnings (Loss) Per Share                                          
Common shares excluded from computation 1,000,000 1,100,000                                      
Cash, Cash Equivalents and Short-term Investments                                          
Maturity period of cash and cash equivalents, maximum 3 months                                        
Maturity period of short term investments, minimum 3 months                                        
Concentrations of Credit Risk                                          
FDIC insured amount 250,000                                        
Cash deposits 12,300,000   11,100,000                                    
Concentration risk, number of customers                                   2 2    
Concentration risk, percentage of accounts receivable                                   65.00% 75.00%    
Property and Equipment                                          
Estimated useful life of assets       3 years 10 years                                
Depreciation 100,000 100,000                                      
Goodwill and Other Identifiable Intangible Assets                                          
Finite-lived intangible asset, useful life 20 years                                        
Amortization expense 600,000 600,000                                      
Amortization Expense                                          
Amortization expense 2014 2,400,000                                        
Amortization expense 2015 2,400,000                                        
Amortization expense 2016 2,400,000                                        
Amortization expense 2017 2,400,000                                        
Amortization expense 2018 2,400,000                                        
Acquired In-Process Research and Development                                          
Impairment of in-process research and development                                       0 0
Commercial License Rights                                          
Number of commercial license agreement programs           15                              
Purchase price           4,600,000                              
Payments to acquire intangible assets           3,600,000                              
Cash payment due on first anniversary of the closing           1,000,000                              
Contingent Liabilities                                          
Contingent liability                   17,600,000                      
Purchase of commercial license rights                     4,300,000 1,600,000 0                
Fair value of liability             7,200,000   9,300,000           6,700,000   4,200,000        
Contingent liability change in amount             500,000 1,800,000             2,500,000 0          
Number of contingent value rights                           4              
Number of contingent value rights per series of contingent value rights                           1              
Number of contingent value rights issued for each share                           4              
Contingent value rights, frequency of cash payment                           6 months              
Revenue Recognition                                          
Period allowed for return of products, minimum 30 days                                        
Period allowed for return of products, maximum 90 days                                        
Treasury stock, shares     1,118,222                                    
Allowance for Doubtful Accounts                                          
Accounts receivable outstanding considered past due after period, minimum 30 days                                        
Accounts receivable outstanding considered past due after period, maximum 90 days                                        
Allowance for doubtful accounts 0   0                                    
Sale of Royalty Rights                                          
Deferred revenue 0   100,000                                    
Discontinued Operations                                          
Number of drugs included in product line 4                                        
Gain on sale of Avinza Product Line before income taxes $ 0 $ 191,000                                      
Segment Reporting                                          
Number of reportable segments 2